Monocyte CD169 expression as a biomarker in the early diagnosis of COVID-19

Monocyte CD169 expression as a biomarker in the early diagnosis of COVID-19

We assessed the expression of CD169, a type I interferon-inducible receptor, on monocytes (mCD169) in 53 adult patients admitted to the hospital during the COVID-19 outbreak for a suspicion of SARS-CoV-2 infection. mCD169 was strongly overexpressed in 30 out of 32 (93.7%) confirmed COVID-19 cases, c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infectious diseases 2021-02, Vol.223 (4), p.562-567
Hauptverfasser: Bedin, Anne-Sophie, Makinson, Alain, Picot, Marie-Christine, Mennechet, Frank, Malergue, Fabrice, Pisoni, Amandine, Nyiramigisha, Esperance, Montagnier, Lise, Bollore, Karine, Debiesse, Ségolène, Morquin, David, Veyrenche, Nicolas, Renault, Constance, Foulongne, Vincent, Bret, Caroline, Bourdin, Arnaud, Le Moing, Vincent, van de Perre, Philippe, Tuaillon, Edouard
Format: Artikel
Sprache:eng
Schlagworte:
Brief Report
Life Sciences
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We assessed the expression of CD169, a type I interferon-inducible receptor, on monocytes (mCD169) in 53 adult patients admitted to the hospital during the COVID-19 outbreak for a suspicion of SARS-CoV-2 infection. mCD169 was strongly overexpressed in 30 out of 32 (93.7%) confirmed COVID-19 cases, compared to three out of 21 (14.3%) patients in whom the diagnosis of COVID-19 was finally ruled out. mCD169 was associated with the plasma interferon alpha level and thrombocytopenia. mCD169 testing may be helpful for the rapid triage of suspected COVID-19 patients during an outbreak.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiaa724